Select Page

CannBerry Tek

Is a Hi-tech innovative Biotechnology Company which manages various Research & Development (“R&D”) activities with the major focus on the Medical Cannabis industry.
Who We AreContact Us

About CannBerry Tek

 

CannBerryTek, Inc. holds 100% of CannBerryTek Ltd. CannBerryTek Ltd. – a Hi-tech innovative Biotechnology Company will manage various Research & Development (“R & D”) activities with the major focus on the Medical Cannabis industry.

CannBerryTek Ltd. (“CannBerry”) has assembled a powerful highly experienced R&D management team to operate in Israel. During the initial phase, CannBerryTek Ltd. intends to focus on generating and developing a unique man-made repository of seeds known as a Cannabis Genetic Seed Bank to create and secure rare, hard-to-find or difficult to legally obtain Cannabis seed types and varieties.

In that regard, CannBerryTek Ltd. intends to apply unique proprietary technological tools developed by its management to monitor Cannabis under sterile conditions in a fully controlled environment. During the second phase, CannBerryTek Ltd. intends to form unique Active Pharmaceutical Ingredient formulations to develop specific Cannabis-based products for the Medical Cannabis industry. An Active Pharmaceutical Ingredient is any substance or mixture of substances intended to be used in the manufacture of a drug (medicinal) product and that, when used in the production of a drug, becomes an active ingredient of the drug product. Such substances are intended to furnish pharmacological activity or other direct effect in the diagnosis, cure, mitigation, treatment, or prevention of disease or to affect the structure or function of the body. CannBerryTek Ltd.’s mission is to become a leading supplier of superior genetics as well as Active Pharmaceutical Ingredients to the Cannabis industry.

CannBerryTek Ltd. is under advanced discussions with Shiva Medical Care Center ( among the top 10 worldwide  Medical Center)  to establish joint venture in implementing Cannabis products to fight most aggressive cancers

In order to reinforce its Product varieties and R & D capabilities, CannBerry intends to leverage its close relationships with leading Cannabis Research Centers including but not limited to the Agricultural Research Organization – Volcani Center (http://www.moag.gov.il/en/About%20the%20Ministry/ministry_sites/Pages/agricultural_research_organization.aspx), Weizmann Institute of Science (https://www.weizmann.ac.il/pages/), Hebrew University Agriculture Faculty (https://en.hafakulta.agri.huji.ac.il/) and Technion’s Faculty of Medicine – Bruce Rappaport Faculty of Medicine (https://md.technion.ac.il/about/) and Tel Aviv University Agricultural Research Center to establish R & D Joint Ventures.

Also under progress discussions with

Potential sources of income from the development of proprietary strains are (1) licensing of premium genetic strains (2) wholesale seed sales (3) clone fulfillment services (4) custom breeding programs and (5) tissue culture and strain patenting services.

 

Our Team

Dan Oran

Dan Oran

Chairman

Niv Yonani

Niv Yonani

CEO

Hanoch Tempelhof

Hanoch Tempelhof

COO

 

CannBerry Tek is a self-sufficient, full-vertical company that covers from seed to cannabis-based pharmaceutical product. Founded as a leading scientific research company, the organization initially cultivated for researchers at the ARO, Israel’s leading governmental Agriculture Research Institute.

The company expanded on its knowledge of growing for research purposes and has subsequently scaled up to include global and commercial cultivation.

CannBerry Tek carefully selects top-notch professionals that work in a synergetic environment to enable the highest quality products, including:

Run the research, create the requirements and control the process

Plant specifications and operations

 

Breeding for patented strains

Experts in GMP growing for medical uses

Enabling quick TTM with quality products

Contact Us

2 + 11 =